Status: Recruiting
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Participants needed: 40
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: He HuangUpdated: Oct 16, 2023Locations: 1
Eligibility criteria
1. Those who voluntarily participated in this trial and provided informed consen... [+10]
1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovas... [+13]